Amyloid beta A4 protein — Drug Target

All drugs that target Amyloid beta A4 protein — marketed and clinical-stage. Includes 6 drug classes acting on this target.

Drug classes

Amyloid Beta-directed Antibody [EPC] · Radioactive Diagnostic Agent [EPC] · Vitamin A · Amyloid Beta-directed Antibody · Standardized Chemical Allergen [EPC] · Anti-coagulant

Marketed (11)

• Leqembi · Eisai · Amyloid Beta-directed Antibody [EPC] · Immunology
  Leqembi works by binding to and removing amyloid beta A4 protein from the brain, which is thought to contribute to the progression of Alzheimer's disease.
• ADUHELM · BIOGEN INC · Neuroscience
• Amyvid · Invicro · Rare Disease
• Vizamyl · GE HealthCare · Radioactive Diagnostic Agent [EPC] · Immunology
  Vizamyl works by binding to amyloid beta A4 protein in the brain, allowing for visualization of amyloid deposits in PET imaging.
• M.V.I. Pediatric · Pfizer · Vitamin A · Immunology
• Aduhelm · Biogen · Amyloid Beta-directed Antibody · Immunology
• Neuraceq · Piramal Imaging · Radioactive Diagnostic Agent [EPC] · Neuroscience
• Cliquinol · Standardized Chemical Allergen [EPC] · Infectious Disease
• LEQEMBI · EISAI INC · Amyloid Beta-directed Antibody [EPC] · Neuroscience
• Calcium Disodium Versenate · Medicis · Anti-coagulant · Rare Disease
• Amyvid · Avid Radiopharms Inc · Radioactive Diagnostic Agent [EPC] · Neuroscience
  Amyvid works by binding to amyloid beta A4 protein in the brain, allowing for visualization of amyloid plaques in Alzheimer's disease.